Industry trailblazer, Myrtle Potter assumes the role of CEO for Sumitovant after having served as Vant Operating Chair of Roivant Sciences since 2018. In that role she oversaw thirty-five investigational drugs in eleven therapeutic areas being tested in over fifty clinical trials across the Roivant family of companies. She brings a proven track record of building and leading high-performance teams to bring successful drugs to market. As CEO of Myrtle Potter & Company she and her 150+ hand-picked team of experts led major strategic efforts and multiple product launches for numerous biopharmaceutical companies. As President and COO and of Genentech, she oversaw 5X revenue growth in 5 years to $5 billion resulting in record sales and earnings growth for 19 of 20 consecutive quarters. Prior to joining Genentech, she served as president of Bristol-Myers Squibb’s $4 billion, 3,500-person U.S. Cardiovascular/Metabolics business. While at Merck she started the company Astra-Merck which later, through a series of transactions became Astra-Zeneca. Potter is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the board of Liberty Mutual Insurance Group, and has served on the boards of Amazon, Axsome Therapeutics, Express Scripts and Medco.
A track record of success. Running faster than the pack.
“Our team has a proven record developing and commercializing therapies that improve patient care and outcomes”.
[image placeholder – do not delete]
The foremost purpose of each of our leadership teams is to provide support, guidance and expertise to ensure the success of each development program within our portfolio of companies. Cognizant of our role as a critical growth engine for Sumitomo Dainippon Pharma, we continually seek new assets to enhance our robust and diverse pipeline and are transforming the drug development process to deliver new medicines to market faster.
We bring new medicines to patients more rapidly.Dan Rothman, Chief Information Officer
Q&A with Dan Rothman, Chief Information Officer at Sumitovant
Sumitovant’s Chief Information Officer, Dan Rothman, elaborates on our key technology platforms and how they may potentially help us bring new medicines more quickly to those who need them most.
Salomon Azoulay, M.D., serves as the Chief Medical Officer and Head of Research & Development of Sumitovant. In this role he oversees numerous functions including clinical development, CMC, Regulatory, and medical affairs functions. Dr. Azoulay previously served as Chief Medical Officer of Roivant Sciences. He joined Roivant from Pfizer, where he most recently served as Senior Vice President and Chief Medical Officer for Pfizer Essential Health. In that role he oversaw clinical development and medical affairs for a portfolio that included over 600 branded products as well as biosimilars and sterile injectables. He has over 25 years of experience in the biopharmaceutical industry and held senior leadership roles at Pfizer since 2001, including Head of Development in Japan and Senior Vice President for Medical and Development in Emerging Markets.
Dan Rothman currently serves in dual leadership roles as Chief Information Officer for Sumitovant Biopharma and Chief Digital Officer for parent company Sumitomo Dainippon Pharma where he has built an entire digital ecosystem across both organizations. This includes establishing platforms such as data engineering and DevOps, building a digital strategy team, and leading enterprise technology and infrastructure, all designed to unlock new value through novel applications of technology. His team has doubled in size annually since inception and identified more than 50 solutions that improve drug discovery, accelerate clinical trials and improve commercialization. Previously he was the Chief Information Officer for Roivant Sciences.
Dan is an innovative leader with a proven track record of leveraging technology to drive digital and behavioral transformation across businesses. He is highly skilled at building and inspiring teams to achieve organizational growth through technology and has specific expertise in applying technology to traditional sectors including healthcare and finance.
Dan’s approach to applied technology has been formed through his unique career journey. After graduating with bachelor’s and master’s degrees in electrical engineering and computer science from MIT, Dan spent a brief time in Silicon Valley as a computer chip designer before embarking on a 20-year career in finance with firms including Goldman Sachs and Lehman Brothers. During this time, he built trading, sales and analytics businesses and revolutionized them with the application of new technology approaches. Dan carried these learnings to his career in pharmaceuticals, looking for opportunities where technology can disrupt how value is created and how to solve business problems through existing methodologies applied in alternate ways.
Yuichiro Haruyama serves as Chief Financial Officer and a member of the board of Sumitovant Biopharma. Mr. Haruyama was instrumental in creating the broad strategic partnership between Sumitomo Dainippon Pharma and Roivant Sciences in 2019, including forming Sumitovant Biopharma. He started his career at Sumitomo Chemical, a leading Japanese chemical company, in 1993 and, since then, he has played a leading role in global pharmaceutical/chemical operations, corporate strategy, business development and finance. At Sumitomo Chemical, he was responsible for designing and implementing strategy for OLED (organic light-emitting diode) business, including a number of partnerships with global electronics companies, as well as oversaw its global operations. As Sumitomo Dainippon Pharma, he served as a key member in developing the corporate mid-term business plan in 2019, setting up and managing global business operations, such as the U.S., UK and Chinese affiliate companies, and leading a number of M&A efforts. Mr. Haruyama earned a Bachelor of Science degree in Business and Commerce at Keio University in Tokyo and an MBA in finance from Indiana University in Bloomington, Indiana.